Business / Finance

RSS

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

HMS Holdings reports third quarter 2013 financial and operating results

HMS Holdings Corp. (NASDAQ:HMSY) today announced it will report its third quarter 2013 financial and operating results at 8:00 a.m. Central/9:00 a.m. Eastern on Friday, November 8, 2013. Supplemental financial information including the press release and presentation will be available at http://investor.hms.com/events.cfm at approximately 7:30 a.m. Eastern on November 8.

19 Oct 2013

Luden partners with Thompson Square to celebrate "Voices Worth Hearing"

Luden's, the soothing throat drop loved by voices everywhere, today announced a new partnership with Thompson Square, the reigning Academy of Country Music and Country Music Association "Vocal Duo of the Year."

19 Oct 2013

Gentiva Health Services completes acquisition of Harden Healthcare Holdings

Gentiva Health Services, Inc., the largest provider of home health and hospice services in the United States based on revenue, announced the closing of its acquisition of Harden Healthcare Holdings, Inc..

18 Oct 2013

Genalyte Gets Grant From NCI To Develop Biomarker Panel For Cancer

...

18 Oct 2013

CIRM President Steps Down After Six Years

...

18 Oct 2013

Ariad Ends Phase III Leukemia Drug Trial

...

18 Oct 2013

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant), successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS), has issued an Interim Final Award in favor of Anacor, awarding Anacor $100 million in damages as well as all costs of the arbitration and reasonable attorney's fees.

18 Oct 2013

NIH Getting Back To Business As Shutdown Ends

...

17 Oct 2013

Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs

...

17 Oct 2013

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

17 Oct 2013

Danaher net earnings increase 9% to $597 million in Q3 2013

Danaher Corporation today announced results for the third quarter of 2013. All financial metrics in this release reflect only the Company's continuing operations and all references to increases in financial metrics reflect year-over-year changes, unless otherwise noted.

From Danaher 17 Oct 2013

AmpliPhi, University of Leicester partner to develop novel bacteriophage therapy against C. difficile

AmpliPhi BioSciences Corporation, the leader in the development of bacteriophage-based antibacterial therapies to treat antibiotic resistant infections, announces it has entered into Collaboration and License Agreements with UK-based University of Leicester to develop a novel bacteriophage therapy targeting Clostridium difficile, a serious gastrointestinal infection for which new treatments are urgently required.

17 Oct 2013

Ceram hosts free webinar on ‘How Clean is Your Device?’

Ceram, the international materials technology company, will be hosting a free webinar, ‘How Clean is Your Device?’ on Thursday 21 November at 3pm (UK time).

17 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

Biotech CEO Faces Felony Charge Of Computer Trespass

...

16 Oct 2013

Pieris Inks Co-Development Alliance With Zydus For Protein Drugs

...

16 Oct 2013

CEO Faces Felony Charge Of Computer Trespass

...

16 Oct 2013

CEL-SCI, Ergomed To Co-Develop Head And Neck Cancer Candidate As Potential HPV Treatment

...

16 Oct 2013

SAGE Therapeutics obtains $20M Series B financing from two investors

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced a $20 million Series B financing from investors ARCH Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011.

16 Oct 2013